Eisai Co., Ltd.
4523・Prime Market・Pharmaceuticals
Governance
As a company with a Nomination Committee, etc., it has an 11-member Board of Directors (7 of whom are outside directors), and outside directors serve as the chair of the Board of Directors and the chairs of the Nomination, Audit, and Compensation Committees, respectively. It has also established an hhc Governance Committee composed solely of outside directors, achieving a clear separation between management oversight and business execution.
Risk Management
The company has established a Risk Management Committee chaired by the Executive Officer in charge of internal control, and identifies and manages significant company-wide risks by conducting a CSA (Control Self-Assessment) annually for all executive officers. Cyber attacks, information security, and compliance-related matters are designated as key risks, and the company continuously addresses them through a PDCA cycle in coordination with its global internal audit system.
Shareholder Returns
The annual dividend for fiscal year 2025 (FY2026, ending March 2026) is ¥160 per share (interim ¥80, year-end ¥80), unchanged from the previous fiscal year. The payout ratio is 117.0%, and DOE is 5.2%. The forecast for FY2026 (FY2027, ending March 2027) also maintains an annual dividend of ¥160. Share buybacks will be considered in light of financial condition and market environment.
Dividend Policy
The Company will implement sustainable and stable dividends, comprehensively taking into account consolidated business results, payout ratio, and free cash flow. The annual dividend for fiscal year 2025 (FY2026, ending March 2026) is ¥160 per share (interim ¥80, year-end ¥80), unchanged from the previous fiscal year. Total dividends amount to ¥45,138 million, with a payout ratio of 117.0% and DOE of 5.2%. The forecast for fiscal year 2026 (FY2027, ending March 2027) also maintains a policy of an annual dividend of ¥160 (interim ¥80, year-end ¥80). Regarding share buybacks, the Company will consider them while taking into account the total payout ratio, based on its financial condition and market environment.
ESG
The company supports the TCFD recommendations and has obtained approval for its SBT 1.5°C target, aiming to reduce Scope 1+2 CO2 emissions by 55% by FY2030 (ending March 2031) compared to FY2019 (ending March 2020) levels (a 51.6% reduction achieved as of the end of FY2024 (ending March 2025)), and has achieved a renewable energy ratio of 98.7%. In terms of human capital, the company has achieved a female manager ratio of 14.3% (target of 30% or more by FY2030 (ending March 2031)) and 85% highly engaged employees in its global engagement survey, and is also actively working to improve access to medicines, including the free provision of NTD treatments to the WHO.
Last updated: June 12, 2026